On Monday, TD (TSX:TD) Cowen initiated coverage on shares of Alkermes (NASDAQ:ALKS), assigning a Buy rating to the stock with a price target of $34.00. The firm's coverage begins with a positive outlook on the biopharmaceutical company, particularly highlighting the potential of its lead pipeline asset, ALKS 2680, an orexin-2 receptor agonist currently in a Phase II study for narcolepsy treatment.
The ongoing Phase II study is focused on patients with narcolepsy type 1 (NT1), and according to TD Cowen, there is significant potential for ALKS 2680 to change the current treatment paradigm for this sleep disorder. The firm suggests that the current market valuation of Alkermes reflects only the existing base business, implying that there could be substantial growth opportunities should the orexin pipeline progress successfully.
TD Cowen's commentary indicates a belief that the advancement of ALKS 2680 could lead to an increase in the company's stock value. The firm's analysis suggests that the market has not yet fully appreciated the potential impact of the new treatment on Alkermes' overall business.
Alkermes is known for its focus on developing innovative therapies in the fields of neuroscience and oncology. The company's pipeline includes a variety of drugs aimed at addressing central nervous system (CNS) disorders, with ALKS 2680 being a key asset among them.
The initiation of coverage by TD Cowen with a Buy rating and a $34.00 price target reflects a confidence in Alkermes' growth prospects, driven by its promising pipeline. As the Phase II study of ALKS 2680 continues, investors and patients alike will be watching for results that could validate the firm's optimistic stance on the company's future.
In other recent news, Alkermes, a neuroscience company, has reported a year-over-year growth of 9%, with total revenues reaching $350.4 million in the first quarter of 2024. The company's net sales for VIVITROL, ARISTADA, and LYBALVI were $97.7 million, $78.9 million, and $57 million respectively, contributing significantly to the revenue. Alkermes also maintains a strong cash and investment balance of $807.8 million and a total debt of $290.1 million.
In parallel, BofA Securities maintained a Neutral rating on Alkermes' stock, revising its price target to $29 from the previous $29, following a slight shortfall in sales and earnings per share in the company's recent earnings report. However, BofA Securities believe that this does not pose a threat to the company's financial guidance for the fiscal year 2024.
Alkermes is also making progress with its pipeline, notably with ALKS 2680 for narcolepsy, which is now in Phase 2 trials. The drug is an orexin-2 receptor agonist and is considered an essential component of the company's future prospects. However, phase 2 data, which are expected to be available in the second half of 2025, still need to be addressed.
InvestingPro Insights
Alkermes (NASDAQ:ALKS) has garnered a favorable outlook from TD Cowen, and a closer look at the company's financials through InvestingPro provides additional insights. Notably, Alkermes holds a significant cash position, with more cash than debt on its balance sheet, which can be a reassuring sign for investors considering the company's financial stability. Furthermore, the company's valuation implies a strong free cash flow yield, which could indicate that the stock is undervalued relative to its cash-generating ability.
On the metrics front, Alkermes boasts a robust gross profit margin of 85.31% for the last twelve months as of Q1 2024, reflecting efficient operations and a strong market position for its products. Additionally, the company's revenue growth is impressive, with a 54.01% increase over the last twelve months as of Q1 2024, which could signal a solid trajectory for future earnings potential. Moreover, the P/E Ratio (Adjusted) stands at a modest 7.18, suggesting that the stock could be an attractive option for value investors.
For those interested in deeper analysis, there are 6 additional InvestingPro Tips available for Alkermes, which could further inform investment decisions. Readers looking to explore these insights can use the coupon code PRONEWS24 to receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.